Introduction
============

The amyloid-beta peptide (Aβ) is a normal subnanomolar component of biological fluids ([@B37]); however, its deposition in the form of amyloid plaques is one of the hallmarks of AD ([@B54]). Amyloid plaques are associated with neuronal loss and cognitive impairment ([@B43]), and they enhance the tau pathology ([@B19]). The trigger of the pathologic Aβ aggregation in AD is unknown ([@B43]); however, in animal models of AD, the conversion of a monomeric Aβ into fibrillar aggregates, through neurotoxic oligomers, is triggered by chemically and structurally modified Aβ species ([@B38]; [@B51]; [@B28]). Amyloid plaques are abnormally rich in Fe, Cu, and Zn ions ([@B9]), and data from animal models suggest that the formation of amyloid plaques is zinc dependent ([@B15]; [@B14]; [@B10]; [@B24]). It has been assumed that zinc ions promote Aβ aggregation via a population shift of polymorphic states ([@B40]). Zinc-induced aggregation of Aβ is governed by its metal-binding domain (Aβ~16~), which comprises the N-terminal region (residues 1--16) of Aβ ([@B22]). It has recently been shown that the metal-binding domain of Aβ containing isomerized Asp7 (isoD7-Aβ~16~) is more prone to zinc-induced oligomerization ([@B22]), suggesting a role for Asp7 isomerization in the initiation of the pathological aggregation process. Indeed, a full-length isoD7-Aβ~42~ peptide is more neurotoxic than the unmodified peptide ([@B41]) and is able to trigger cerebral amyloidosis *in vivo* ([@B30]). Thus, the ability of Aβ to form zinc-induced aggregates may correlate with its amyloidogenic and neurotoxic properties.

Recently, it has been shown that Aβ undergoes phosphorylation at Ser8 both *in vitro* and *in vivo* ([@B34], [@B35]). In the absence of zinc ions, phosphorylated Aβ (pS8-Aβ) was found to be a fast-aggregating peptide species, producing stable fibrillar aggregates and neurotoxic oligomers *in vitro* ([@B52]; [@B23]). In the presence of Zn^2+^, the metal-binding domain of pS8-Aβ (pS8-Aβ~16~) forms stable dimers ([@B33]); however, in contrast to the zinc-mediated behavior of similar domains in several other Aβ isoforms (including native Aβ), the zinc-bound dimers of pS8-Aβ~16~ do not give rise to larger oligomers and aggregates ([@B22]). Moreover, the zinc-driven heterodimers formed between pS8-Aβ~16~ and isoD7-Aβ~16~ or Aβ~16~ also cannot oligomerize. We hypothesized that pS8-Aβ~42~ does not aggregate in the presence of zinc ions and that pS8-Aβ~42~ can prevent the aggregation of native Aβ through the formation of non-propagating heterodimers between pS8-Aβ~42~ and Aβ ([@B39]). By contrast, phosphorylation at Ser8 may change the interaction of Aβ with other proteins, such as Na^+^,K^+^-ATPase. Previously, it was shown that Na^+^,K^+^-ATPase activity was inhibited in post-mortem tissues of AD patients and in amyloid-containing hippocampi of transgenic mice (but not in the amyloid-free cerebellum) ([@B11]; [@B32]; [@B62]). The latest studies demonstrated that Aβ~42~ in form of monomers or oligomers directly binds to Na^+^,K^+^-ATPase, which results in the inhibition of the enzyme as well as the triggering of intracellular signaling cascades ([@B47]; [@B49]). Therefore, phosphorylation at Ser8 might neutralize some pathogenic properties of Aβ. Furthermore, the concentration of pS8-Aβ is very likely to change with age since brain aging is associated with changes in the activity of kinases and phosphatases in nerve tissue ([@B26]; [@B45]). An age-related shift in the neuronal protein phosphorylation has recently been shown in *Drosophila* models ([@B58]). Thus, phosphorylated Aβ species could be significant for the development of late-onset AD. However, there are no published data on the zinc-dependent oligomerization and related properties of a full-length pS8-Aβ peptide. In the present study, we investigated the role of pS8-Aβ~42~ as a potential quencher of zinc-induced oligomerization of endogenous Aβ species and of pathological effects associated with this process, such as the inhibition of Na^+^,K^+^-ATPase and induction of cerebral amyloidosis, in AD model mice.

Materials and Methods {#s1}
=====================

Host Mice
---------

B6C3-Tg(APPswe,PSEN1dE9)85Dbo mice were used at the age of 2--8 months (weight of 24--26 g). Mice were housed in the Pushchino Animal Breeding Facility (branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences), under specific pathogen-free conditions. Housing and use of laboratory animals were approved by the commission IACUC, protocol No. 479/15 from 16.03.15. All animal manipulations were performed according to recommendations of the Guide for the Care and Use of Laboratory Animals (NRC 2011), the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, Council of Europe (ETS 123). The experimental procedures were approved by the local Animal Care and Use Committee (Reg. No. 126/15 from March 31, 2015). The study was supported by the Federal Agency for Scientific Organizations Program for Support of the Bioresource Collections.

Reagents
--------

All chemicals and solvents used throughout this study were of HPLC-grade or better and were obtained from Sigma-Aldrich (St. Louis, MO, United States) unless otherwise stated. Synthetic peptides (purity \[98%\] checked by RP-HPLC) Aβ~42~ (\[H2N\]-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-\[COOH\]) and pS8-Aβ~42~ (\[H2N\]-DAEFRHD\[pS\]GYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-\[COOH\]) were purchased from Biopeptide (San Diego, CA, United States). The amino acid sequence of the peptide was confirmed with an ultra-high resolution Fourier transform ion cyclotron resonance mass-spectrometer 7T Apex Qe BRUKER (Bruker Daltonics, Bellerica, MA, United States) utilizing a *de novo* sequencing approach based on a CID fragmentation technique as described earlier ([@B21]).

Aβ Peptides Preparations
------------------------

### Synthetic pS8-Aβ~42~ Preparations for Injections

Two thousand micrograms of peptide pS8-Aβ~42~ were dissolved in 2000 μL of sterile physiological saline (PS), then the prepared solution was filtered through a 0.22-μm filter (Millex-GV, Millipore), aliquoted to 125 μL and frozen. For injection, one aliquot was thawed, sterile PS was added to obtain 1500 μL of solution with a peptide concentration of 0.08333 μg/μL ("administration solution"). Then, 150 μL of "administration solution" were withdrawn and 125 μL of this solution were injected into one animal. Thus, with a single injection, 10 μg of the peptide were ingested.

The aggregation state of the synthetic peptide pS8-Aβ~42~ in the samples used for the injections, characterized by us using a standard test based on thioflavin T ([@B4]), did not change during the time of storage (1--8 months), and did not differ from that of the freshly prepared solutions of the corresponding peptides.

### Synthetic Aβ~42~ and pS8-Aβ~42~ Preparations for Na,K-ATPase Studies

To prepare working solutions of Aβ~42~ and pS8-Aβ~42~ peptides, cold hexafluoroisopropanol ("Fluka") was added to dry Aβ to a concentration of 1 mM and incubated for 60 min at room temperature. The resulting solution was then placed in ice for 10 min and transferred to non-siliconized microcentrifuge tubes (0.56 mg peptide per tube). The peptides in the tubes were vacuum-dried with Eppendorf Concentrator 5301. The resulting dry peptides were stored at −80°C. A fresh 2.5 mM Aβ solution was prepared by adding 20 μl of 100% anhydrous dimethyl sulfoxide ("Sigma") to 0.56 mg of the peptide, followed by incubation for 1 h at room temperature.

### Synthetic Aβ~42~ and pS8-Aβ~42~ Preparations for DLS Measurements

To measure the average diameter of Aβ aggregates, synthetic peptides Aβ~42~ and pS8-Aβ~42~ were treated with hexafluoroisopropanol, dried, and dissolved in 10 mM NaOH at concentration of 0.5 mM. Peptides were brought to required concentrations in 10 mM HEPES (pH 7.4) supplemented with 150 mM NaCl, using appropriate buffers.

Dynamic Light Scattering
------------------------

Dynamic light scattering measurements were carried out using a Zetasizer Nano ZS apparatus (Malvern Instruments, Ltd., United Kingdom) at 25°C in accordance with the manufacturer instruction. The instrument is equipped with a He-Ne laser source (λ = 632.8 nm) and operates in the back-scatting mode, measuring particle size in the range between 0.6 nm and 10 μm. The particle size distribution is estimated with a spherical approximation of particles, employing a CONTIN data analysis utility available as a part of the instrument software, and used to calculate the average particle diameter (*D*). The aggregation of Aβ~42~ and pS8-Aβ~42~ peptides was triggered by diluting peptide solutions with a ZnCl~2~-containing buffer so as to provide a twofold molar excess of zinc ions over peptides.

Turbidimetry
------------

A peptide/zinc mixture was placed in a BRAND UV microcuvette (BRAND GMBH, Germany) and its turbidity was monitored in time (at room temperature) as optical density at 405 nm, using an Agilent 8453E spectrophotometer (Agilent Technologies, United States). Turbidity measurements were started in 0.5 min after triggering the zinc-induced Aβ aggregation as described for the DLS experiments. The initial (zero time) points were measured in the absence of zinc ions, using 25-μM Aβ solutions.

Intravenous Injections
----------------------

Retro-orbital injections of the venous sinus in mice were performed according to [@B61]. Mice received one retro-orbital injection with 1-month intervals between injections. The contents of injections for each group of mice are described in **Table [1](#T1){ref-type="table"}**. The mice were assigned to the various groups randomly.

###### 

Suppression of congophilic amyloid plaques formation in the brain of B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J transgenic mice.

               Transgenic mice   Injection   Brain sections   Number of amyloid plaques per section                   Statistical significance                 
  ------------ ----------------- ----------- ---------------- ------------------------------------------------------- -------------------------- ------------- -------------
  PS           4 (2+2)           2           8                PS (125 μl)                                             40                         28.7 ± 4.6    --
  pS8-Aβ~42~   5 (2+3)           2           8                Synthetic pS8- Aβ~42~ peptide (10 μg in 125 μl of PS)   50                         18.3 ± 0.94   *P* \< 0.05

Histology and Immunohistochemistry
----------------------------------

Euthanasia procedure was applied to 8-month-old mice. Mouse euthanasia was carried out by CO~2~ according to the IACUC-approved protocol with the use of automated CO~2~-box Bioscape (Germany). Mice were transcardially perfused with 50 mL of PBS, followed by 50 mL of 4% paraformaldehyde (PFA). Mouse brains were fixed in 10% formalin. Process for paraffin embedding was scheduled as follow: 75% ethanol overnight, 96% ethanol 5 min, 96% ethanol 10 min, 100% ethanol 10 min (two changes), ethanol--chloroform (1:1) 30 min, chloroform overnight. Paraffin embedding was performed at 60°C for 3 h (three changes). The embedding of tissues into paraffin blocks was done using Leica EG1160 device. Serial brain sections (8 um) were cut using microtome Leica RM2265 mounted onto slides. For deparaffinization, hydration and staining of the sections the following steps were done: slides were consistently put in xylene three changes (10 min each), 96% ethanol (5 min), 90% ethanol (2 min), 75% ethanol (2 min), H~2~O three changes (5 min each), Congo Red solution (5 min), potassium alkali solution, and water. The Immu-Mount medium (Thermo Scientific) was used for mounting.

Immunostaining was carried out as described elsewhere ([@B30]). Briefly, sections were deparaffinized and after antigen retrieval by microwaving in citrate buffer washed in PBS and blocked with 10% goat serum in 0.04% Tween20 in PBS (T-PBS). Sections were incubated with primary antibody for 2 h at room temperature, washed thrice in T-PBS, incubated with secondary antibody for 1 h at room temperature followed by washing in T-PBS. The mouse anti-human Aβ monoclonal antibodies 6E10 (Covance, Dallas, TX, United States) diluted in the block solution 1:1000 were used as the primary antibodies, Alexa Fluor 488 goat anti-mouse antibodies (Invitrogen, Grand Island, NY, United States) were used as the secondary antibodies for immunofluorescence staining (dilution 1:1000 in T-PBS). The images were captured with Leica DFS490 digital camera (Leica Microsystems, Wetzlar, Germany) at 100x magnification using Leica DMI 4000 fluorescent microscope (Leica Microsystems, Wetzlar, Germany).

Quantitative Assessment of Cerebral β-Amyloidosis
-------------------------------------------------

The sections spanning brain from 0.48 to 1.92 mm relative to the midline in lateral stereotaxic coordinates were used to quantify congophilic amyloid plaques in the hippocampus. Every 15th section was analyzed, yielding 10 sections per animal. Amyloid plaques were identified by Congo Red staining and manually counted as described previously ([@B44]; [@B2]) using Zeiss Axiovert 200 M microscope with 10×, 20×, and 40× objectives (Carl Zeiss, Oberkochen, Germany), with examination under bright-field and between crossed polarizers. Amyloid plaques of all sizes were accepted for counting if they were visible and met the following requirements: red coloring under bright-field and the green birefringence in polarized light. Analyses were undertaken by two researchers independently (EB, SK). To determine the reproducibility of the plaques counts, an intra-class correlation (ICC) was calculated yielding good inter-rater reliability between the two researchers (ICC \> 0.85). For each group of mice, the average values (± SD) of the plaques number per section were calculated.

Hydrolytic Activity of Na^+^/K^+^-ATPase
----------------------------------------

The purified preparation of Na^+^/K^+^-ATPase (α1β1 isozyme) was obtained from duck salt glands as described elsewhere ([@B49]). The purity grade of Na^+^/K^+^-ATPase was 99% and specific activity of the enzyme reached ∼2400 μmol of Pi (mg of protein × h)^−1^ at 37°C.

Hydrolytic activity of Na^+^/K^+^-ATPase in the purified preparation was measured as ouabain-sensitive (1 mM) ATP cleavage in the reaction medium containing 130 mM NaCl, 20 mM KCl, 3 mM MgCl~2~, 3 mM ATP, and 30 mM imidazole, pH 7.4, 37°C as elsewhere ([@B49]). Stock solutions containing Aβ~42~ and pS8-Aβ~42~ peptides, prepared as described above, were added to the reaction medium (without ATP) up to a concentration of 40 μM. An equivalent amount of DMSO was added to the control samples. Following 3--60 min of pre-incubation with amyloid peptides, the enzymatic reaction was started by adding ATP.

Modeling of the Structure of pS8-Aβ42:Na^+/^K^+^-ATPase Complex
---------------------------------------------------------------

Model of the pS8-Aβ~42~ peptide was constructed using as templates the Aβ~42~ structure modeled in [@B49]. The resulting model of pS8-Aβ~42~ was minimized in the AMBER99 force field with the AutoDockTools program. Modeling of the pS8-Aβ~42~:Na^+^/K^+^-ATPase complex was performed using the structure of Na^+^/K^+^-ATPase from shark glands 2zxe (PDB id) solved at 2.4 Å resolution ([@B56]), and the modeled structure of pS8-Aβ~42~. Docking has been carried out with VinaAutoDock program ([@B59]), and the docking was constrained to cover only the extracellular part of the protein.

Isothermal Titration Calorimetry (ITC)
--------------------------------------

The thermodynamic parameters of amyloid peptides binding to Na^+^/K^+^-ATPase were measured using a MicroCal iTC200 instrument, as described elsewhere ([@B42]; [@B50]). Experiments were carried out at 25°C in 10 mM imidazole buffer (pH 7.5), containing 130 mM NaCl, 30 mM KCl, 3 mM MgCl~2~. Aliquots (2.6 μl) of ligands were injected into a 0.2-ml cell containing protein solution to achieve a complete binding isotherm. Protein concentration in the cell ranged from 10 to 20 μM, and ligand concentration in the syringe ranged from 100 to 200 μM. The resulting titration curves were fitted using the MicroCal Origin software, assuming one set of binding sites. Affinity constants (Ka), enthalpy variations (ΔH) and stoichiometry of binding (N) were determined and the Gibbs energy (ΔG) and entropy variations (ΔS) were calculated from the equation: ΔG = −RTlnKa = ΔH-TΔS.

Statistical Methods Used for Data Analysis
------------------------------------------

Data are presented as means of at least three independent experiments ± SD. The Mann--Whitney test was used for pairwise comparison between examined groups of mice; *P* \< 0.05 was considered significant. The comparison of Na^+^/K^+^-ATPase data groups was performed using one-way ANOVA with *post hoc* testing (using paired samples Student's *t*-test with Bonferroni correction); after a Bonferroni correction a *P*-value \< 0.016 was considered as statistically significant. Statistical analysis was performed using STATISTICA 8.0 (StatSoft, Inc., Tulsa, OK, United States).

Results
=======

pS8-Aβ~42~ Suppresses Zinc-Dependent Aggregation of Aβ~42~
----------------------------------------------------------

Using DLS, we observed a time-dependent formation of Aβ~42~ or pS8-Aβ~42~ in the presence of Zn^2+^ (**Figure [1A](#F1){ref-type="fig"}**). Prior to zinc addition, only oligomers 20--30 nm in size were detected. In the absence of zinc ions, there were no appreciable changes in the characteristic size of both Aβ~42~ and pS8-Aβ~42~ oligomers during the 90 min incubation period (at 25°C and quiescent conditions). After 10 min of incubation with Zn^2+^, the characteristic diameter of Aβ~42~ aggregates reached 700--800 nm, and it became more than 2,000 nm by the end of the observation period (100 min). In contrast, pS8-Aβ~42~ did not form aggregates larger than 50 nm in the presence of zinc ions during the entire observation period. The results of the turbidity measurements support those of DLS experiments (**Figure [1B](#F1){ref-type="fig"}**): Ser8 phosphorylation substantially suppressed the propensity of Aβ peptides for zinc-triggered aggregation, which was manifested in the remarkably higher turbidity of the Aβ~42~/Zn^2+^ mixture than that of the pS8-Aβ~42~/Zn^2+^ mixture. The effect of Ser8 phosphorylation on zinc-induced Aβ aggregation was the opposite of that on spontaneous Aβ aggregation: as revealed in the ThT assay, in the absence of zinc ions, pS8-Aβ~42~ aggregates much faster than Aβ~42~ (**Supplementary Figure [1](#SM1){ref-type="supplementary-material"}**). This result is consistent with those reported by [@B34], [@B35]).

![Characterization ofx the zinc-induced aggregation of Aβ~42~ and pS8-Aβ~42~ peptides. Measurements were performed in 10 mM HEPES (pH 7.3), 150 mM NaCl. **(A)** The characteristic diameter (*D*) of zinc-induced aggregates of Aβ~42~ and pS8-Aβ~42~ was monitored with DLS. White circles -- Aβ~42~, black circles -- pS8-Aβ~42~. Peptide and zinc ion concentrations -- 25 and 50 μM, respectively. **(B)** Aβ solution turbidity (optical density at 405 nm, OD~405~) in the presence (circles) and absence (triangles) of zinc ions was monitored over 30 min. The normalized turbidity was obtained by dividing the OD~405~ values by the highest OD~405~ value observed (OD~405~ = 0.055). White symbols -- Aβ~42~; Black symbols -- pS8-Aβ~42~. Peptide and zinc concentrations as in **(A)**. **(C)** The relative size of zinc-induced Aβ aggregates at the incubation time of 70 min in solutions with different pS8-Aβ~42~/Aβ~42~ molar ratios. *D*~0~ -- the size of zinc-induced aggregates in Aβ~42~ solution (without pS8-Aβ~42~) at this time point. Aβ~42~ and zinc ion concentrations were of 25 and 50 μM at each pS8-Aβ~42~/Aβ~42~ molar ratio tested. The dashed lines indicate IC~50~ (≈9 μM; this value corresponds to about one pS8-Aβ~42~ peptide per three Aβ~42~ peptides). Data are mean values for three independent experiments ± SD. Size of the white circles in **(A)** is larger than the error bars. Error bars for **(B)** are not shown.](fnmol-11-00302-g001){#F1}

To study a possible effect of pS8-Aβ~42~ on the zinc-induced aggregation of Aβ~42~, we determined the characteristic size of zinc-induced aggregates in a series of pS8-Aβ~42~/Aβ~42~ mixtures with different molar ratios of the peptides (**Figure [1C](#F1){ref-type="fig"}**) at the 70-min time point (the time point at which *D* reaches a plateau at a zinc/Aβ~42~ molar ratio of 1:3; **Supplementary Figure [2](#SM1){ref-type="supplementary-material"}**). When equimolar mixtures of pS8-Aβ~42~ and Aβ~42~ (12.5 μM each) were tested in the presence of 50 μM Zn^2+^, the aggregate diameter decreased to (45 ± 10) nm. Thus, mixing of pS8-Aβ~42~ peptides with the unmodified peptide strongly suppressed the zinc-dependent aggregation of the latter. The half-maximal inhibitory concentration (IC~50~) for pS8-Aβ~42~ was estimated, under the conditions tested, to be approximately 9 μM (**Figure [1C](#F1){ref-type="fig"}**); this value corresponds to about one pS8-Aβ~42~ peptide per three Aβ~42~ peptides.

![Representative polarized light micrographs of brain sections through the hippocampus for 8-months-old B6C3-Tg(APPswe, PSEN1dE9)85Dbo/j transgenic mice intravenously injected by sterile PS **(A)** or synthetic pS8-Aβ~42~ peptide **(B)**. Amyloid plaques are highlighted by white bars. Scale bars: **(A,B)**: 100 μm.](fnmol-11-00302-g002){#F2}

Injection of pS8-Aβ~42~ Reduces the Amyloid Load in the Hippocampus of Transgenic AD Model Mice
-----------------------------------------------------------------------------------------------

We examined the ability of the synthetic pS8-Aβ~42~ peptide to reduce the cerebral amyloidogenesis in an APP/PS1 doubly transgenic murine model of AD. These mice have cognitive features of an AD-like pathology and accumulate significant amounts of dense-core congophilic amyloid plaques starting from 4 to 6 month of age, regardless of the sex ([@B5]; [@B16]). The experimental groups, which included male and female animals, were subjected to retro-orbital injections of peptide pS8-Aβ~42~ (10 μg in 125 μL of PS) starting from 2 months of age. After serial (at monthly intervals) inoculations with the peptide, the host mice were sacrificed at the age of 8 months. The brains were extracted, and sagittal brain sections (8-μm thick) were analyzed histochemically using Congo Red staining. The hippocampus was chosen as the target region for manual counting of the stained congophilic amyloid plaques using bright-field microscopy in the sections representing the brain layer located between 0.48 and 1.92 mm relative to the midline in lateral stereotaxic coordinates. The congophilic plaques found in the brains of all experimental animals were similar in terms of their location and size distribution in the brain parenchyma (**Figure [2](#F2){ref-type="fig"}**). Additionally, immunohistochemical characterization of the congophilic amyloid plaques revealed the presence of Aβ (**Supplementary Figure [3](#SM1){ref-type="supplementary-material"}**). Quantitative analysis revealed a significantly lower number of congophilic amyloid plaques per section in the pS8-Aβ~42~-inoculated 8-month-old transgenic mice (−36.3%, *P* \< 0.05) than that in the untreated littermates (**Figure [2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**).

![Interaction of Na^+^/K^+^-ATPase with beta-amyloid peptides. **(A)** Hydrolytic activity of purified Na^+/^K^+^-ATPase was measured after 60 min incubation with 40 μM of Aβ~42~ or pS8-Aβ~42~. The histogram represents the enzyme activity in the presence or absence of amyloid peptides, the enzyme activity without Aβ~42~ is accepted as 100%. Data are mean values for three independent experiments ± SD. Statistical analysis was performed using one-way ANOVA (*F* = 1894.8, degree of freedom 2, *P* \< 0.00001) with *post hoc* testing (using paired samples Student's *t*-test with Bonferroni correction); after a Bonferroni correction, a *P*-value \< 0.016 was considered as statistically significant; ^∗^*P* \< 0.001. ITC titration curves (upper panels) and binding isotherms (lower panels) for Aβ~42~ **(B)**, pS8-Aβ~42~ **(C)**, and Aβ~17-42~ **(D)** interaction with Na,K-ATPase at 25°C.](fnmol-11-00302-g003){#F3}

pS8-Aβ~42~ Binds to Na^+^,K^+^-ATPase Without Inhibiting Its Hydrolytic Activity
--------------------------------------------------------------------------------

For the measurements, we used purified Na^+^,K^+^-ATPase from duck salt glands, which is a homolog of the α1β1 human isozyme. Earlier, we have demonstrated that the unmodified Aβ~42~ inhibits the hydrolytic activity of the enzyme ([@B49]). In contrast to Aβ~42~, which inhibited Na^+^,K^+^-ATPase after 60-min incubation with 40 μM peptide, pS8-Aβ~42~ had no effect on enzyme activity (**Figure [3A](#F3){ref-type="fig"}**). The interaction of Na^+^,K^+^-ATPase with the Aβ~42~ and pS8-Aβ~42~ peptides was measured by ITC (**Figures [3B,C](#F3){ref-type="fig"}**). The stoichiometry of binding to Na^+^,K^+^-ATPase was equal to 1 for both peptides, demonstrating that the peptides were predominantly in a monomeric state, as we have shown previously for Aβ~42~ ([@B49]). The binding constants of Aβ~42~ and pS8-Aβ~42~ with the enzyme were close to each other, and the energy profiles \[enthalpy (ΔH) and entropy (TΔS)\] for binding of both peptides were practically the same (**Table [2](#T2){ref-type="table"}**). This indicates that phosphorylation of Aβ does not affect the peptide interaction with Na^+^,K^+^-ATPase.

###### 

Thermodynamic parameters of Aβ~42~ and pS8-Aβ~42~ binding to Na^+^/K^+^-ATPase determined by ITC at 25°C.

  Ligand       Ka M^−1^      Kd μM   ΔH kcal/mol   TΔS kcal/mol   ΔG kcal/mol
  ------------ ------------- ------- ------------- -------------- -------------
  Aβ~42~       7.7 × 10^5^   1.3     −2.54         5.48           −8.02
  pS8-Aβ~42~   4.5 × 10^5^   2.2     −2.54         5.19           −7.73
  Aβ~17--42~   2.6 × 10^5^   3.8     −2.27         5.13           −7.4
  Aβ~16~       nd            --      nd            --             --

Ka, affinity constant; standard deviation did not exceed 30%. Kd, dissociation constant; calculated as 1/K. ΔH, enthalpy variation; standard deviation did not exceed 10%. TΔS, entropy variation; calculated from the equation ΔG = ΔH-TΔS. ΔG, Gibbs energy; calculated from the equation ΔG = RTlnKa. nd, not detected.

Hydrophobic C-Terminal Domain of Aβ~42~ Is Responsible for Its Binding to Na^+^,K^+^-ATPase
-------------------------------------------------------------------------------------------

Structure analysis of the Aβ~42~:Na^+^,K^+^-ATPase complex, which we performed earlier ([@B49]), has shown that the Ser8 residue is located outside of the interaction site (**Figure [4](#F4){ref-type="fig"}**). Introduction of the phosphate group to Ser8 had no effect on the conformation of the Aβ~42~ polypeptide chain and did not change the interaction interface (**Figure [4](#F4){ref-type="fig"}**).

![The model of Na^+^/K^+^-ATPase:pS8-Aβ~42~ peptide complex on the basis of 2zxe PDB structure. Na^+^/K^+^-ATPase is shown as a translucent gray molecular surface, C-terminal part (17--42) of pS8-Aβ~42~ peptide is shown in green and the N-terminal metal-binding domains (1--16) is shown in yellow. The phosphorylated Ser8 residue is located outside of the interaction region (highlighted in red). The zinc-binding site 11--14 and pSer8 residue are shown by the ball and stick representation.](fnmol-11-00302-g004){#F4}

Binding parameters of the N-terminal zinc-binding domain, Aβ~1-16~, and C-terminal hydrophobic fragment, Aβ~17-42~, to Na^+^,K^+^-ATPase were determined by ITC. Binding was detectable for the 17--42 fragment (**Figure [3D](#F3){ref-type="fig"}**) but not for the 1--16 fragment (**Table [2](#T2){ref-type="table"}**).

Metal-Dependent Aggregation of Aβ~42~ and pS8-Aβ~42~ Correlates With Their Ability to Inhibit Na^+^,K^+^-ATPase
---------------------------------------------------------------------------------------------------------------

Using DLS, we showed that Mg^2+^ at concentrations of 3 mM and above induces the aggregation of Aβ~42~ after 10 min of incubation (**Supplementary Figure [4](#SM1){ref-type="supplementary-material"}**). By contrast, no oligomers of pS8-Aβ~42~ were observed even after 20 min of incubation with 10 mM Mg^2+^. Since Na^+^,K^+^-ATPase activity was measured in a buffer containing 3 mM Mg^2+^, we hypothesized that Mg^2+^-dependent oligomers of Aβ~42~ are required to inhibit Na^+^,K^+^-ATPase and the absence of such aggregates in pS8-Aβ~42~ solution determines the absence of inhibition. To support this conclusion, we measured the Na^+^,K^+^-ATPase inhibition by Aβ~42~ at different time points and found that the degree of inhibition increases over time and plateaus after 30 min of incubation (**Supplementary Figure [5](#SM1){ref-type="supplementary-material"}**). However, Aβ~42~ incubated in Mg^2+^-containing solution for 30 min (in the absence of Na^+^,K^+^-ATPase) did not inhibit Na^+^,K^+^-ATPase if the activity was measured immediately after the addition of the oligomers to the enzyme-containing solution (**Supplementary Figure [6](#SM1){ref-type="supplementary-material"}**). Since both Aβ~42~ and pS8-Aβ~42~ are able to bind to Na^+^,K^+^-ATPase, we hypothesized that the initial binding of Aβ peptides to the enzyme acts as a seed for further aggregation of Aβ on the enzyme matrix and results in the inhibition of the enzyme. In the case of pS8-Aβ~42~, binding to the enzyme is not followed by oligomerization, which explains the absence of inhibition.

![The possible role of pS8-Aβ~42~ in maintaining brain health. In healthy brain synapses **(A)**, the release of Zn^2+^ during synaptic transmission does not cause Aβ accumulation, as phosphorylated Aβ does not form zinc-induced aggregates and also prevents zinc-induced aggregation of the intact peptide through the formation of heterodimers. Phosphorylated Aβ does not inhibit Na^+^/K^+^-ATPase (NKA) and the heterodimers are easily cleared, therefore the synapse function is not impaired. If pS8-Aβ~42~ is depleted **(B)**, synaptic release of zinc ions promotes oligomerization of Aβ, inhibition of Na^+^,K^+^-ATPase and, eventually, leads to the amyloid plaques formation, which impairs the synapse function.](fnmol-11-00302-g005){#F5}

Discussion
==========

Since it was first proposed by Hardy in 1992, the amyloid hypothesis of AD has undergone a number of changes ([@B54]). The focus of research has shifted from senile plaques to soluble toxic oligomers of Aβ, and the inherent role of the tau-protein in the AD pathogenesis has been elucidated. Accumulation and aggregation of Aβ are still considered triggers of the AD pathological cascade ([@B43]); however, recent failures of monoclonal antibodies against Aβ in clinical trials call for reassessment of the role of Aβ in AD pathogenesis ([@B1]). It is possible that the pivotal factor is not the total amount of Aβ in the blood but the range and relative quantities of modified Aβ species. A number of different modified Aβ forms, such as isomerized ([@B53]; [@B55]), pyroglutamylated ([@B60]; [@B46]), truncated ([@B36]), and other peptides, have been identified in senile plaques. Previously identified chemical modifications of Aβ seem to increase the pathogenic properties of the peptide. However, based on the present data, Ser8 phosphorylation could be the first identified modification that reverses some disease-associated properties of Aβ.

Protein phosphorylation is a ubiquitous modification, which tightly and precisely regulates the structural and functional characteristics of proteins ([@B20]; [@B8]). Aberrant protein phosphorylation is a disease-modifying factor, one of the most prominent examples of which is the hyperphosphorylation of tau in AD ([@B8]; [@B3]). Recently, pS8-Aβ was obtained *in vitro* by Aβ phosphorylation with protein kinase A and was subsequently identified *in vivo* ([@B34], [@B35]). Based on the oligomeric state of pS8-Aβ derived from brain tissue of AD model mice ([@B35]) and accelerated aggregation of pS8-Aβ~40~ *in vitro*, [@B34] have proposed that pS8-Aβ represents a potentially pathogenic agent in AD. However, the aggregation of pS8-Aβ was previously studied in the absence of divalent cations, particularly zinc ions, which are involved in both physiological processes and AD pathogenesis ([@B57]; [@B14]; [@B34]; [@B23]). In a complex with Aβ, zinc ions can form seeds of pathogenic aggregation ([@B13]; [@B40]; [@B7]). This is especially likely to occur in synapses, where concentrations of Zn^2+^ may reach 100s of micromoles per liter ([@B48]).

We have previously shown that phosphorylation of Aβ at Ser8 leads to an increase in the zinc-dependent dimerization of Aβ ([@B33]). Zinc-induced dimerization of the unmodified Aβ occurs through residues 11EVHH14 ([@B31]), and the His6 residue is recruited for further oligomerization ([@B22]). However, in pS8-Aβ dimers, His6 forms an additional intramolecular Zn^2+^-binding site with the pSer8 residue, which thereby excludes the His6 residue from further oligomerization ([@B33]). Thus, phosphorylation should lead to a decrease in the ability of Aβ to form zinc-induced aggregates. We investigated the effect of Ser8 phosphorylation on the pathogenic properties of the Aβ species Aβ~42~, which is more prone to aggregation than Aβ~40~ and seems to trigger the disease in a number of models ([@B25]; [@B27]; [@B17]). As expected, Ser8 phosphorylation reduced the zinc-driven aggregation of Aβ~42~. The formation of aggregates in an equimolar mixture of pS8-Aβ~42~ and Aβ~42~ was also dramatically suppressed. This may be due to the fact that pS8-Aβ~42~ forms zinc-induced heterodimers with the unmodified Aβ~42~, which are not capable of further aggregation. Formation of heterodimers between the metal-binding domains of Aβ and pS8-Aβ was previously observed *in vitro* ([@B39]).

We hypothesized that *in vitro* inhibition of zinc-dependent aggregation by pS8-Aβ~42~ will result in an anti-amyloidogenic effect *in vivo*. To test the hypothesis, we studied the effect of retro-orbital injections of pS8-Aβ~42~ on the progression of cerebral amyloidosis in a murine model of AD, B6C3-Tg(*APPswe,PSEN1dE9*)85Dbo/j. We have previously found that retro-orbital injection of isoD7-Aβ~42~, but not of Aβ~42~, promoted the amyloid plaque formation in mice of this line ([@B30]). It was the first evidence of the facilitation of cerebral amyloidosis by a synthetic Aβ species injected into the bloodstream. The ability of blood-derived Aβ to induce AD-like pathology has recently been confirmed in a murine parabiosis model ([@B6]); however, the authors have not identified the Aβ species that triggered the pathogenesis. It is important to mention that isoD7-Aβ~42~ exhibits increased zinc-dependent oligomerization *in vitro* ([@B22]), and may serve as a seed of zinc-dependent aggregation of Aβ in brains of transgenic mice. In the case of pS8-Aβ~42~, which is unable to form zinc-dependent aggregates, we expected to observe an opposite effect. Indeed, the number of plaques in the hippocampus of the transgenic mice that received pS8-Aβ~42~ injections was approximately two-third of that in the mice that received PS injections. Apparently, pS8-Aβ~42~ is unable to serve as an aggregation seed *in vivo* and also partially prevents the amyloidogenic aggregation of the endogenous Aβ peptides. Based on zinc-dependent aggregation of the Aβ~42~/pS8-Aβ~42~ mixture *in vitro*, it is likely that pS8-Aβ~42~ forms heterodimers with Aβ~42~ in the nerve tissue, which prevents the formation of senile plaques. This indicates that bloodstream-derived Aβ can serve not only as a trigger but also as an obstacle for cerebral amyloidosis progression, depending on the Aβ species composition. These findings further support the role of zinc-induced aggregation as an important event in the amyloidogenic process.

It is known that cognitive deficits in AD or in corresponding models do not always correlate with the appearance of amyloid plaques and often appear before Aβ aggregates can be detected ([@B43]). Such effects are associated with soluble toxic oligomers of the Aβ peptide ([@B18]) or with receptor-mediated effects of Aβ ([@B12]). Recently, we have shown that Aβ can bind to Na^+^,K^+^-ATPase ([@B49]), whose activity is critically important for maintaining electrogenic properties of neurons. Here, we found that binding of monomeric Aβ to the enzyme and subsequent oligomerization of the peptide on the Aβ:Na^+^,K^+^-ATPase matrix leads to the inhibition of enzyme activity. This observation provides a possible explanation for the decrease in the activity of Na^+^,K^+^-ATPase in brain tissues of AD patients ([@B62]; [@B29]; [@B49]). Unlike the unmodified peptide, pS8-Aβ~42~ does not show an inhibitory effect on Na^+^,K^+^-ATPase. Surprisingly, the binding parameters of pS8-Aβ~42~ to the enzyme were almost identical to those of the unmodified peptide; thus, it is not the initial binding that defines the inhibitory properties of Aβ~42~ toward Na^+^,K^+^-ATPase. We further showed that the N-terminal domain of Aβ~42~ (including the pS8 residue) is not involved in the initial binding and is probably exposed to the solution. Since the N-terminal domain of the peptide governs its metal-dependent oligomerization, we suggest that the inhibition of Na^+^,K^+^-ATPase is caused by the metal-dependent formation of Aβ oligomers seeded by the solution-exposed N-terminal domain of the first Na,K-ATPase-bound peptide. Phosphorylation of the peptide at Ser8 seems to interfere with this process, which may correspond to its inability to form oligomers triggered by Mg^2+^ (present in Na^+^,K^+^-ATPase activity measurements buffer) or by Zn^2+^. Thus, a decrease in the level of phosphorylation of the peptide in the elderly may lead to the inhibition of Na^+^,K^+^-ATPase, development of neurotoxic effects, and the disruption of nerve transduction long before the appearance of amyloid aggregates. The possible role of Aβ phosphorylation in the brain is presented at **Figure [5](#F5){ref-type="fig"}**.

Conclusion
==========

In this study, we demonstrated that the phosphorylation of Aβ~42~ at Ser8 changes its properties of zinc-driven aggregation, inhibition of Na^+^/K^+^-ATPase, and amyloidogenicity. The obtained data indicate that the phosphorylation of Aβ~42~ neutralizes some of its AD-associated properties. Our findings provide the basis for discussion about the role of Ser8 phosphorylation in Aβ~,~ which was previously considered only as a pathogenic modification. The anti-amyloidogenic properties of pS8-Aβ~42~ *in vivo* support the intrinsic role of zinc-mediated aggregation in the formation of the senile plaques. Further studies addressing the role of pS8-Aβ in the human brain are needed for better clarification of both the significance of pS8-Aβ and the relevance of the obtained data to AD.
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Aβ

:   β-amyloid peptide

Aβ~42~

:   Aβ~16~, Aβ~17-42~, Aβ~40,~ β-amyloid peptide isoforms 1--42, 1--16, 17--42, 1--40, respectively

AD

:   Alzheimer's disease

DLS

:   dynamic light scattering

isoD7-Aβ

:   isomerized Asp7-containing β-amyloid peptide

ITC

:   isothermal titration calorimetry

PDB

:   Protein Data Bank

PS

:   physiological saline

pS8-Aβ

:   phosphorylated Ser8-containing β-amyloid peptide

sAD

:   sporadic Alzheimer's disease.
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